株探米国株
エドガーで原本を確認する
0000001800FALSENew York Stock ExchangeCHX00000018002026-07-162026-07-160000001800exch:XCHI2026-07-162026-07-160000001800exch:XNYS2026-07-162026-07-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
_______________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
July 16, 2026
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
_______________________________________________________

Illinois 1-2189 36-0698440
(State or other Jurisdiction
of Incorporation)		 (Commission File Number) (IRS Employer
Identification  No.)
_______________________________________________________
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class
Trading
Symbol(s)
Name of Each Exchange
on Which Registered
Common Shares, Without Par Value ABT
New York Stock Exchange
NYSE Texas
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 2.02    Results of Operations and Financial Condition
On July 16, 2026, Abbott Laboratories announced its results of operations for the second quarter 2026.
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal reserves, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Item 9.01    Financial Statements and Exhibits
Exhibit No. Exhibit
104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ABBOTT LABORATORIES
Date: July 16, 2026 By: /s/ Philip P. Boudreau
Philip P. Boudreau
Executive Vice President, Finance and Chief Financial Officer

EX-99.1 2 abt-2026q2xexhibitx991.htm EX-99.1 Document

 Exhibit 99.1
image.jpg
  News Release

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

–Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent
–Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31
–Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%1
–Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58
–Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases

ABBOTT PARK, Ill., July 16, 2026 — Abbott today announced financial results for the second quarter ended June 30, 2026.

•Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis.
•Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items.
•Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%1.
•Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58.
•In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial. This trial is designed to evaluate Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation.
•In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company's pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios.
•In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.
•In May, Abbott completed its submission to the U.S. Food and Drug Administration (FDA) seeking approval for the company's Amulet™ 360 left atrial appendage (LAA) device.
•In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options for adults age 45 and older who are at average risk for CRC.

"Our second-quarter results reflect the momentum we are building," said Robert B. Ford, chairman and chief executive officer, Abbott. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."
 
Page 1 of 21

SECOND-QUARTER BUSINESS OVERVIEW

Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
 Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices
U.S. 5,216  871  1,660  —  2,680 
International 7,377  1,273  1,432  1,499  3,173 
Total reported 12,593  2,144  3,092  1,499  5,853 
% Change vs. 2Q25
U.S. 22.0  (9.0) 104.8  n/a 7.0 
International 7.5  1.4  5.1  8.4  10.7 
Total reported 13.0  (3.1) 42.3  8.4  9.0 
Total reported excl. foreign exchange impact 12.2  (3.6) 41.3  8.7  7.9 
Comparable sales growth 4.8  (3.6) 2.9  8.7  8.4 
    U.S. 3.5  (9.0) 4.0  n/a 8.0 
    International 5.8  0.6  1.6  8.7  8.7 

First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
 Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices
U.S. 9,490  1,715  2,565  —  5,203 
International 14,267  2,446  2,707  2,925  6,189 
Total reported 23,757  4,161  5,272  2,925  11,392 
% Change vs. 1H25
U.S. 12.4  (10.3) 52.5  n/a 7.4 
International 9.3  —  6.4  10.7  14.2 
Total reported 10.5  (4.5) 24.7  10.7  11.0 
Total reported excl. foreign exchange impact 8.2  (5.6) 22.4  8.9  8.0 
Comparable sales growth 4.3  (5.6) 2.4  8.9  8.4 
    U.S. 3.0  (10.3) 3.0  n/a 8.3 
    International 5.3  (1.9) 1.6  8.9  8.5 

Refer to pages 16 and 17 for a reconciliation of comparable sales growth.



Page 2 of 21


Nutrition

Second Quarter 2026 Results (2Q26)

Sales 2Q26 ($ in millions)
 Total Pediatric Adult
U.S. 871  525  346 
International 1,273  500  773 
Total reported 2,144  1,025  1,119 
% Change vs. 2Q25
U.S. (9.0) (10.7) (6.4)
International 1.4  7.3  (2.0)
Total reported (3.1) (2.7) (3.4)
Total reported excl. foreign exchange impact (3.6) (3.1) (4.0)
Comparable sales growth (3.6) (3.1) (4.0)
    U.S. (9.0) (10.7) (6.4)
    International 0.6  6.4  (2.8)
Worldwide Nutrition sales decreased 3.1 percent on a reported basis and 3.6 percent on a comparable basis in the second quarter.
Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of new products, are contributing to improving performance. Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026.

First Half 2026 Results (1H26)

Sales 1H26 ($ in millions)
 Total Pediatric Adult
U.S. 1,715  1,036  679 
International 2,446  942  1,504 
Total reported 4,161  1,978  2,183 
% Change vs. 1H25
U.S. (10.3) (11.9) (7.8)
International —  2.4  (1.5)
Total reported (4.5) (5.6) (3.5)
Total reported excl. foreign exchange impact (5.6) (6.4) (4.9)
Comparable sales growth (5.6) (6.4) (4.9)
    U.S. (10.3) (11.9) (7.8)
    International (1.9) 0.7  (3.5)







Page 3 of 21


Diagnostics*

Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
 Total Core Laboratory Cancer Diagnostics Rapid/Molecular Diagnostics
U.S. 1,660  377  890  393 
International 1,432  1,041  29  362 
Total reported 3,092  1,418  919  755 
% Change vs. 2Q25
U.S. 104.8  7.5  n/a (14.5)
International 5.1  3.4  n/a 2.0 
Total reported 42.3  4.4  n/a (7.3)
Total reported excl. foreign exchange impact 41.3  3.2  n/a (8.0)
Comparable sales growth 2.9  3.2  13.3  (8.0)
    U.S. 4.0  7.5  13.3  (14.5)
    International 1.6  1.7  13.8  0.5 

Worldwide Diagnostics sales increased 42.3 percent on a reported basis and 2.9 percent on a comparable basis in the second quarter.
Worldwide Core Laboratory Diagnostics results were driven by strong growth in the U.S. and Latin America.
Rapid and Molecular Diagnostics results reflect lower sales of respiratory virus tests compared to the prior year.
Cancer Diagnostics results were driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat users. Results in the quarter also reflect contributions to growth from the precision oncology and international businesses.

First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
 Total Core Laboratory Cancer Diagnostics Rapid/Molecular Diagnostics
U.S. 2,565  724  983  858 
International 2,707  1,966  32  709 
Total reported 5,272  2,690  1,015  1,567 
% Change vs. 1H25
U.S. 52.5  6.0  n/a (14.1)
International 6.4  6.1  n/a 2.4 
Total reported 24.7  6.1  n/a (7.4)
Total reported excl. foreign exchange impact 22.4  3.2  n/a (8.8)
Comparable sales growth 2.4  3.2  13.3  (8.8)
    U.S. 3.0  6.0  13.2  (14.1)
    International 1.6  2.2  16.5  (1.1)
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.
Refer to pages 16 and 17 for a reconciliation of comparable sales growth.

Page 4 of 21


Established Pharmaceuticals

Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
 Total Key Emerging Markets Other
U.S. —  —  — 
International 1,499  1,164  335 
Total reported 1,499  1,164  335 
% Change vs. 2Q25
U.S. n/a n/a n/a
International 8.4  9.8  3.7 
Total reported 8.4  9.8  3.7 
Total reported excl. foreign exchange impact 8.7  10.7  2.1 
Comparable sales growth 8.7  10.7  2.1 
    U.S. n/a n/a n/a
    International 8.7  10.7  2.1 

Established Pharmaceuticals sales increased 8.4 percent on a reported basis and 8.7 percent on a comparable basis in the second quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.8 percent on a reported basis and 10.7 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions.



First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
 Total Key Emerging Markets Other
U.S. —  —  — 
International 2,925  2,253  672 
Total reported 2,925  2,253  672 
% Change vs. 1H25
U.S. n/a n/a n/a
International 10.7  11.3  8.6 
Total reported 10.7  11.3  8.6 
Total reported excl. foreign exchange impact 8.9  10.1  4.9 
Comparable sales growth 8.9  10.1  4.9 
    U.S. n/a n/a n/a
    International 8.9  10.1  4.9 



Page 5 of 21


Medical Devices

Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
 Total Rhythm Management Electro-physiology* Heart Failure Vascular Structural Heart* Neuro-modulation Diabetes Care
U.S. 2,680  377  420  313  294  225  189  862 
International 3,173  366  441  88  509  372  71  1,326 
Total reported 5,853  743  861  401  803  597  260  2,188 
% Change vs. 2Q25
U.S. 7.0  10.7  15.9  10.9  3.9  (9.8) (2.1) 8.6 
International 10.7  10.0  12.3  3.0  7.5  12.1  14.7  11.7 
Total reported 9.0  10.4  14.0  9.0  6.1  2.7  2.0  10.5 
Total reported excl. foreign exchange impact 7.9  9.5  13.4  8.7  5.1  1.7  1.2  9.0 
Comparable sales growth 8.4  9.5  13.4  8.7  5.1  5.7  1.2  9.0 
    U.S. 8.0  10.7  15.9  10.9  3.9  (0.9) (2.1) 8.6 
    International 8.7  8.3  11.1  1.3  5.8  10.2  11.3  9.2 


Worldwide Medical Devices sales increased 9.0 percent on a reported basis and 8.4 percent on a comparable basis in the second quarter.

Sales growth in the quarter was led by low-teens growth in Electrophysiology and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure.

In Diabetes Care, sales of continuous glucose monitors grew 11.0 percent on a reported basis and 9.5 percent on a comparable basis.


First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
 Total Rhythm Management Electro-physiology* Heart Failure Vascular Structural Heart* Neuro-modulation Diabetes Care
U.S. 5,203  716  798  605  585  449  366  1,684 
International 6,189  711  851  185  995  726  137  2,584 
Total reported 11,392  1,427  1,649  790  1,580  1,175  503  4,268 
% Change vs. 1H25
U.S. 7.4  11.1  14.8  11.1  6.2  (9.6) (0.7) 9.2 
International 14.2  15.9  15.7  13.5  8.7  18.1  20.4  14.0 
Total reported 11.0  13.4  15.3  11.7  7.7  5.7  4.3  12.1 
Total reported excl. foreign exchange impact 8.0  10.9  13.0  10.4  5.0  2.6  2.6  8.2 
Comparable sales growth 8.4  10.9  13.0  10.4  5.0  6.2  2.6  8.2 
    U.S. 8.3  11.1  14.8  11.1  6.2  (2.2) (0.7) 9.2 
    International 8.5  10.7  11.2  7.8  4.3  12.4  13.2  7.5 

*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.

Refer to pages 16 and 17 for a reconciliation of comparable sales growth.


Page 6 of 21


Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60.

Abbott projects third-quarter 2026 adjusted diluted earnings per share of $1.38 to $1.46.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.
Abbott Declares 410th Consecutive Quarterly Dividend
On June 12, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.


About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

Page 7 of 21


— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Abbott Financial:
Michael Comilla, 224-668-1872
Tamika McLoughlin, 224-399-5082
Randy Blakley, 224-668-0036
Abbott Media:
Karen Twigg May, 224-668-2681
Kate Dyer, 224-668-9965

1.In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott’s Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million.

Page 8 of 21


Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Second Quarter Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)




2Q26 2Q25 % Change
Net Sales $12,593 $11,142 13.0 
Cost of products sold, excluding amortization expense 5,325  4,854  9.7 
Amortization of intangible assets 658  420  56.8 
Research and development 892  725  22.9 
Selling, general, and administrative 4,025  3,091  30.3 
Total Operating Cost and Expenses 10,900  9,090  19.9 
Operating Earnings 1,693  2,052  (17.5)
Interest expense, net 299  50  n/m
Net foreign exchange (gain) loss 4  (11) n/m
Other (income) expense, net (134) (137) (2.5)
Earnings before taxes 1,524  2,150  (29.1)
Taxes on Earnings 596  371  60.8  1)
Net Earnings $928 $1,779 (47.8)
Net Earnings excluding Specified Items, as described below $2,290 $2,213 3.5  2)
Diluted Earnings per Common Share $0.53 $1.01 n/m
Diluted Earnings per Common Share, excluding Specified Items, as described below $1.31 $1.26 4.0  2)
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,743  1,751 
NOTES:
See tables on page 13 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.

Page 9 of 21


1)2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.362 billion, or $0.78 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.

Page 10 of 21


Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
First Half Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)




1H26 1H25 % Change
Net Sales $23,757 $21,500 10.5 
Cost of products sold, excluding amortization expense 10,215  9,322  9.6 
Amortization of intangible assets 1,080  840  28.5 
Research and development 1,659  1,441  15.1 
Selling, general, and administrative 7,765  6,152  26.2 
Total Operating Cost and Expenses 20,719  17,755  16.7 
Operating Earnings 3,038  3,745  (18.9)
Interest expense, net 367  99  n/m
Net foreign exchange (gain) loss (9) (18) n/m
Other (income) expense, net (293) (264) 10.6 
Earnings before taxes 2,973  3,928  (24.3)
Taxes on earnings 968  824  17.5  1)
Net Earnings $2,005 $3,104 n/m
Net Earnings excluding Specified Items, as described below $4,312 $4,132 4.4  2)
Diluted Earnings per Common Share $1.14 $1.77 n/m
Diluted Earnings per Common Share,
excluding Specified Items, as described below
 $2.46 $2.35 4.7  2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
 1,745  1,749 



NOTES:
See tables on page 14 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.

Page 11 of 21


1)2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $2.307 billion, or $1.32 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, restructuring, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.028 billion, or $0.58 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

Page 12 of 21


Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Second Quarter Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
2Q26
As Reported (GAAP) Specified Items As Adjusted
Intangible Amortization
 $ 658  $ (658) $ — 
Gross Margin
 6,610  697  7,307 
R&D
 892  (25) 867 
SG&A
 4,025  (428) 3,597 
Other (income) expense, net
 (134) (27) (161)
Earnings before taxes
 1,524  1,177  2,701 
Taxes on Earnings
 596  (185) 411 
Net Earnings
 928  1,362  2,290 
Diluted Earnings per Share
 $ 0.53  $ 0.78  $ 1.31 

Specified items reflect intangible amortization expense of $658 million and other net expenses of $519 million associated with acquisitions, legal reserves, investment impairments, and other net expenses. See page 18 for additional details regarding specified items.
2Q25
As Reported (GAAP) Specified Items As Adjusted
Intangible Amortization
 $ 420  $ (420) $ — 
Gross Margin
 5,868  478  6,346 
R&D
 725  (20) 705 
SG&A
 3,091  (1) 3,090 
Other (income) expense, net
 (137) (1) (138)
Earnings before taxes
 2,150  500  2,650 
Taxes on Earnings
 371  66  437 
Net Earnings
 1,779  434  2,213 
Diluted Earnings per Share
 $ 1.01  $ 0.25  $ 1.26 

Specified items reflect intangible amortization expense of $420 million and other net expenses of $80 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See page 19 for additional details regarding specified items.

Page 13 of 21


Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
First Half Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
1H26
As
Reported (GAAP)		 Specified Items As
Adjusted
Intangible Amortization
 $ 1,080  $ (1,080) $ — 
Gross Margin
 12,462  1,129  13,591 
R&D
 1,659  (49) 1,610 
SG&A
 7,765  (901) 6,864 
Other (income) expense, net
 (293) (34) (327)
Earnings before taxes
 2,973  2,113  5,086 
Taxes on Earnings
 968  (194) 774 
Net Earnings
 2,005  2,307  4,312 
Diluted Earnings per Share
 $ 1.14  $ 1.32  $ 2.46 

Specified items reflect intangible amortization expense of $1.080 billion and other net expenses of $1.033 billion associated with restructuring actions, acquisitions, legal reserves, investment impairments, and other net expenses. See page 20 for additional details regarding specified items.
1H25
As
Reported (GAAP)		 Specified Items As
Adjusted
Intangible Amortization
 $ 840  $ (840) $ — 
Gross Margin
 11,338  926  12,264 
R&D
 1,441  (47) 1,394 
SG&A
 6,152  (11) 6,141 
Other (income) expense, net
 (264) (36) (300)
Earnings before taxes
 3,928  1,020  4,948 
Taxes on Earnings
 824  (8) 816 
Net Earnings
 3,104  1,028  4,132 
Diluted Earnings per Share
 $ 1.77  $ 0.58  $ 2.35 

Specified items reflect intangible amortization expense of $840 million and other net expenses of $180 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See page 21 for additional details regarding specified items.


Page 14 of 21


A reconciliation of the second-quarter tax rates for 2026 and 2025 is shown below:
2Q26
($ in millions) Pre-Tax
Income		 Taxes on
Earnings		 Tax
Rate
As reported (GAAP) $ 1,524  $ 596  39.1 % 1)
Specified items 1,177  (185)
Excluding specified items $ 2,701  $ 411  15.2 %
2Q25
($ in millions) Pre-Tax
Income		 Taxes on
Earnings		 Tax
Rate
As reported (GAAP) $ 2,150  $ 371  17.3 % 2)
Specified items 500  66 
Excluding specified items $ 2,650  $ 437  16.5 %
1)2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below:

1H26
($ in millions) Pre-Tax
Income		 Taxes on
Earnings		 Tax
Rate
As reported (GAAP) $ 2,973  $ 968  32.5 % 3)
Specified items 2,113  (194)
Excluding specified items $ 5,086  $ 774  15.2 %

1H25
($ in millions) Pre-Tax
Income		 Taxes on
Earnings		 Tax
Rate
As reported (GAAP) $ 3,928  $ 824  21.0 % 4)
Specified items 1,020  (8)
Excluding specified items $ 4,948  $ 816  16.5 %

3)2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

4)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 15 of 21


Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Second Quarter Ended June 30, 2026 and 2025
($ in millions)
(unaudited)

2Q26 2Q25 % Change vs. 2Q25
Non-GAAP
Abbott Reported Foreign exchange Comparable Revenue Abbott Reported Impact of acquisition (a) Impact
of multi-year agreement (b)		 Comparable Revenue Reported Comparable
Total Company 12,593  (86) 12,507  11,142  811  (22) 11,931  13.0  4.8 
U.S. 5,216  —  5,216  4,276  786  (22) 5,040  22.0  3.5 
Intl 7,377  (86) 7,291  6,866  25  —  6,891  7.5  5.8 
Total Diagnostics 3,092  (22) 3,070  2,173  811  —  2,984  42.3  2.9 
U.S. 1,660  —  1,660  811  786  —  1,597  104.8  4.0 
Intl 1,432  (22) 1,410  1,362  25  —  1,387  5.1  1.6 
Total Cancer Diagnostics 919  —  919  —  811  —  811  n/a 13.3 
U.S. 890  —  890  —  786  —  786  n/a 13.3 
Intl 29  —  29  —  25  —  25  n/a 13.8 
Total Medical Devices 5,853  (57) 5,796  5,369  —  (22) 5,347  9.0  8.4 
U.S. 2,680  —  2,680  2,503  —  (22) 2,481  7.0  8.0 
Intl 3,173  (57) 3,116  2,866  —  —  2,866  10.7  8.7 
Total Structural Heart* 597  (6) 591  581  —  (22) 559  2.7  5.7 
U.S. 225  —  225  249  —  (22) 227  (9.8) (0.9)
Intl 372  (6) 366  332  —  —  332  12.1  10.2 

*
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 were moved from Structural Heart to Electrophysiology.
a)
The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.
b) Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.


Page 16 of 21


Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
First Half Ended June 30, 2026 and 2025
($ in millions)
(unaudited)

1H26 1H25 % Change vs. 1H25
Non-GAAP
Abbott Reported Impact of acquisition (a) Impact
of multi-year agreement (b)		 Foreign exchange Comparable Revenue Abbott Reported Impact of acquisition (a) Impact
of multi-year agreement (b)		 Comparable Revenue Reported Comparable
Total Company 23,757  706  (8) (500) 23,955  21,500  1,518  (46) 22,972  10.5  4.3 
U.S. 9,490  681  (8) —  10,163  8,444  1,470  (46) 9,868  12.4  3.0 
Intl 14,267  25  —  (500) 13,792  13,056  48  —  13,104  9.3  5.3 
Total Diagnostics 5,272  706  —  (98) 5,880  4,227  1,518  —  5,745  24.7  2.4 
U.S. 2,565  681  —  —  3,246  1,682  1,470  —  3,152  52.5  3.0 
Intl 2,707  25  —  (98) 2,634  2,545  48  —  2,593  6.4  1.6 
Total Cancer Diagnostics 1,015  706  —  (1) 1,720  —  1,518  —  1,518  n/a 13.3 
U.S. 983  681  —  —  1,664  —  1,470  —  1,470  n/a 13.2 
Intl 32  25  —  (1) 56  —  48  —  48  n/a 16.5 
Total Medical Devices 11,392  —  (8) (306) 11,078  10,264  —  (46) 10,218  11.0  8.4 
U.S. 5,203  —  (8) —  5,195  4,842  —  (46) 4,796  7.4  8.3 
Intl 6,189  —  —  (306) 5,883  5,422  —  —  5,422  14.2  8.5 
Total Structural Heart* 1,175  —  (8) (35) 1,132  1,112  —  (46) 1,066  5.7  6.2 
U.S. 449  —  (8) —  441  497  —  (46) 451  (9.6) (2.2)
Intl 726  —  —  (35) 691  615  —  —  615  18.1  12.4 

*
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.
a)
The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.
b) Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.






Page 17 of 21


Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2026
(in millions, except per share data)
(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds
Gross Margin $ 32  $ 4  $ 658  $ 3  $ 697 
R&D (10) —  —  (15) (25)
SG&A (42) (1) —  (385) (428)
Other (income) expense, net 1  (1) —  (27) (27)
Earnings before taxes $ 83  $ 6  $ 658  $ 430  1,177 
Taxes on Earnings (d) (185)
Net Earnings $ 1,362 
Diluted Earnings per Share $ 0.78 
The table above provides additional details regarding the specified items described on page 13.

a)Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.
b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.

c)Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 18 of 21


Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2025
(in millions, except per share data)
(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds
Gross Margin $ 1  $ 55  $ 420  $ 2  $ 478 
R&D —  (7) —  (13) (20)
SG&A (3) 1  —  1  (1)
Other (income) expense, net (1) —  —  —  (1)
Earnings before taxes $ 5  $ 61  $ 420  $ 14  500 
Taxes on Earnings (d) 66 
Net Earnings $ 434 
Diluted Earnings per Share $ 0.25 

The table above provides additional details regarding the specified items described on page 13.

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)Reflects the net tax benefit associated with the specified items and the recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 19 of 21


Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2026
(in millions, except per share data)
(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds
Gross Margin $ 34  $ 11  $ 1,080  $ 4  $ 1,129 
R&D (11) (10) —  (28) (49)
SG&A (486) (34) —  (381) (901)
Other (income) expense, net (1) (3) —  (30) (34)
Earnings before taxes $ 532  $ 58  $ 1,080  $ 443  2,113 
Taxes on Earnings (d) (194)
Net Earnings $ 2,307 
Diluted Earnings per Share $ 1.32 
The table above provides additional details regarding the specified items described on page 14.

a)Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.
c)Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 20 of 21


Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2025
(in millions, except per share data)
(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds
Gross Margin $ 1  $ 81  $ 840  $ 4  $ 926 
R&D (1) (23) —  (23) (47)
SG&A (6) (6) —  1  (11)
Other (income) expense, net (25) —  —  (11) (36)
Earnings before taxes $ 33  $ 110  $ 840  $ 37  1,020 
Taxes on Earnings (d) (8)
Net Earnings $ 1,028 
Diluted Earnings per Share $ 0.58 

The table above provides additional details regarding the specified items described on page 14.

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.
d)Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 21 of 21